MYCO and MYCOF Related Headlines

Feb 7, 2024 05:01PM Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

Feb 2, 2024 04:05PM Mydecine Innovations Group Announces Director Resignation

Nov 28, 2023 04:05PM Mydecine Announces Update Regarding the Special Access Program

Oct 31, 2023 02:00AM Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

Oct 5, 2023 05:01PM Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO

Sep 27, 2023 05:18PM Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date

Sep 20, 2023 12:12PM Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing

Sep 19, 2023 04:01PM Mydecine Innovations Announces Closing of Prospectus Supplement Financing

Sep 15, 2023 05:30PM Mydecine Innovations Group Files Prospectus Supplement

Aug 14, 2023 08:32PM Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

Jul 21, 2023 05:30PM Mydecine Innovations Group Provides Corporate Update

May 29, 2023 07:42PM Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors

May 16, 2023 04:01PM Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023

May 10, 2023 04:05PM Mydecine Reports its 2023 Annual General Shareholders' Meeting Results

Apr 24, 2023 11:16AM Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues

MYCO and MYCOF Related Press Releases

Feb 7, 2024 05:01PM Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

Feb 2, 2024 04:05PM Mydecine Innovations Group Announces Director Resignation

Nov 28, 2023 04:05PM Mydecine Announces Update Regarding the Special Access Program

Oct 31, 2023 02:00AM Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

Oct 5, 2023 05:01PM Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO

Sep 27, 2023 05:18PM Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date

Sep 20, 2023 12:12PM Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing

Sep 19, 2023 04:01PM Mydecine Innovations Announces Closing of Prospectus Supplement Financing

Sep 15, 2023 05:30PM Mydecine Innovations Group Files Prospectus Supplement

Aug 14, 2023 08:32PM Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

Jul 21, 2023 05:30PM Mydecine Innovations Group Provides Corporate Update

May 29, 2023 07:42PM Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors

May 16, 2023 04:01PM Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023

May 10, 2023 04:05PM Mydecine Reports its 2023 Annual General Shareholders' Meeting Results

Apr 24, 2023 11:16AM Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues

MYCO and MYCOF Related SEC Filings